Drug-Eluting versus Bare-Metal Stents in Large Coronary Arteries
Christoph KaiserS. GalatiusPaul ErnéFranz R. EberliHannes AlberHans RickliGiovanni PedrazziniBurkhard HornigOsmund BertelPiero O. BonettiStefano De ServiHans‐Peter Brunner‐La RoccaIngrid RicardMatthias Pfisterer
Abstract
In patients requiring stenting of large coronary arteries, no significant differences were found among sirolimus-eluting, everolimus-eluting, and bare-metal stents with respect to the rate of death or myocardial infarction. With the two drug-eluting stents, similar reductions in rates of target-vessel revascularization were seen. (Funded by the Basel Cardiovascular Research Foundation and the Swiss National Foundation for Research; Current Controlled Trials number, ISRCTN72444640.).
Metrics
Citation History
Topics
Related Documents
0234: Drug-eluting stents versus bare-metal stent in large coronary arteries
M. HassineMehdi BoussadaMejdi Ben MassoudMarouen MahjoubZohra DridiFethi BetboutHabib Gamra
Drug-eluting or bare-metal stents in large coronary arteries
Long-term outcomes of drug-eluting stents versus bare-metal stents in large coronary arteries
Ming‐Jer HsiehChun-Chi ChenShang‐Hung ChangChao‐Yung WangCheng‐Hung LeeFen-Chiung LinChee‐Jen ChangChing‐Lin Hsieh
Are drug-eluting stents superior to bare metal stents in large coronary arteries?
Daniel SteinbergSundeep MishraAamir JavaidTina L. Pinto SlottowAshesh N. BuchP. RoyTeruo OkabeKimberly A. SmithXue ZhangNatalie GevorkianWilliam O. SuddathK.M. KentLowell F. SatlerAugusto D. PichardRon Waksman
One-Year clinical outcomes of drug-eluting stents versus bare-metal stents in large coronary arteries
Jayesh PrajapatiRoopesh SinghalIva PatelChirag PatelSibasis Sahoo